| Literature DB >> 23383071 |
Claudia Udine1, Gilles Brackman, Silvia Bazzini, Silvia Buroni, Heleen Van Acker, Maria Rosalia Pasca, Giovanna Riccardi, Tom Coenye.
Abstract
Many putative virulence factors of Burkholderia cenocepacia are controlled by various quorum sensing (QS) circuits. These QS systems either use N-acyl homoserine lactones (AHL) or cis-2-dodecenoic acid ("Burkholderia diffusible signal factor", BDSF) as signalling molecules. Previous work suggested that there is little cross-talk between both types of systems. We constructed mutants in B. cenocepacia strain J2315, in which genes encoding CepI (BCAM1870), CciI (BCAM0239a) and the BDSF synthase (BCAM0581) were inactivated, and also constructed double (ΔcepIΔBCAM0581, ΔcciIΔBCAM0581 and ΔcepIΔcciI) mutants and a triple (ΔcepIΔcciIΔBCAM0581) mutant. Subsequently we investigated phenotypic properties (antibiotic susceptibility, biofilm formation, production of AHL and BDSF, protease activity and virulence in Caenorhabditis elegans) and measured gene expression in these mutants, and this in the presence and absence of added BDSF, AHL or both. The triple mutant was significantly more affected in biofilm formation, antimicrobial susceptibility, virulence in C. elegans, and protease production than either the single or double mutants. The ΔBCAM0581 mutant and the ΔcepIΔBCAM0581 and ΔcciIΔBCAM0581 double mutants produced significantly less AHL compared to the WT strain and the ΔcepI and ΔcciI single mutant, respectively. The expression of cepI and cciI in ΔBCAM0581, was approximately 3-fold and 7-fold (p<0.05) lower than in the WT, respectively. The observed differences in AHL production, expression of cepI and cciI and QS-controlled phenotypes in the ΔBCAM0581 mutant could (at least partially) be restored by addition of BDSF. Our data suggest that, in B. cenocepacia J2315, AHL and BDSF-based QS systems co-regulate the same set of genes, regulate different sets of genes that are involved in the same phenotypes and/or that the BDSF system controls the AHL-based QS system. As the expression of the gene encoding the C6-HSL synthase CciI (and to a lesser extent the C8-HSL synthase CepI) is partially controlled by BDSF, it seems likely that the BDSF QS systems controls AHL production through this system.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23383071 PMCID: PMC3557247 DOI: 10.1371/journal.pone.0055112
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Relative amount of biofilm formation in the various strains compared to WT (average±standard deviation).
Biofilm were formed for 24 h in the absence (CTRL) and presence of signalling molecules (AHL, BDSF or both; 5 µM). N = 60 for all experiments. Black bars: relative amount of metabolically active cells as quantified with CellTiter Blue. Grey bars: relative amount of total biomass as quantified with crystal violet.
Figure 2Representative confocal images of 24-h-old biofilms formed by various B. cenocepacia QS mutants.
MIC (µg/ml) of various antibiotics towards B. cenocepacia J2315 WT and mutant strains.
| MIC (µg/ml) for | |||||
| Strain | CAZ | FOX | CIP | MEM | TOB |
| J2315 | >128 | >128 | 8 | 32 | 256 |
| Δc | >128 | >128 | 8 | 32 | 256 |
| Δ | >128 | >128 | 8 | 32 | 256 |
| Δ | 64 | 128 | 8 | 32 | 256 |
| Δ | 128 | >128 | 8 | 32 | 256 |
| ΔBCAM0581 | 32 | 128 | 8 | 8 | 128 |
| ΔBCAM0581+ BDSF | 64 | >128 | 8 | 16 | 256 |
| Δ | >128 | >128 | 8 | 32 | 128 |
| Δ | >128 | >128 | 8 | 32 | 256 |
| Δ | 32 | 64 | 8 | 8 | 128 |
| Δ | 64 | 128 | 8 | 16 | 256 |
| Δ | 32 | 128 | 8 | 16 | 128 |
| Δ | 64 | >128 | 8 | 32 | 256 |
| Δ | 16 | 64 | 8 | 8 | 128 |
| Δ | 32 | 128 | 8 | 16 | 256 |
CAZ, ceftazidime; FOX, cefoxitin; CIP, ciprofloxacin; MEM, meropenem; TOB, tobramycin.
Figure 3Effect of treatment of mature biofilms with tobramycin (A) or meropenem (B).
Antibiotics were added in a concentration equal to 4×MIC for each strain to 24 old biofilms, grown in the absence (CTRL) or presence of signalling molecules (AHL, BDSF or both; 5 µM). Data are expressed as average log (CFU/biofilm) (±standard deviation). N ≥3 for all experiments. Treatment of the mutants resulted in significantly higher reductions than treatment of the WT (p<0.05). In addition, supplementation resulted in a significant decrease in susceptibility compared to the unsupplemented mutant (p<0.05).
Figure 4Percent survival of C. elegans (average ± standard deviation) infected with various B. cenocepacia strains in the absence (CTRL) or presence of signalling molecules (AHL, BDSF or both; 5 µM).
The results are expressed as the percent survival after 24 h (black bars) or 48 h (grey bars) of infection and treatment. *: significantly different survival compared to uninfected control (p<0.0001); **: significantly different survival compared to infection with WT (p<0.0001).
Figure 5Production of AHL molecules by various B. cenocepacia strains A) in the absence and B) presence of BDSF (5 µM).
*: significantly different from no AHL production (p<0.001); **: significantly different from control receiving no BDSF (p<0.001).
Figure 6Production of BDSF by the ΔcepIΔcciI double mutant.
Biofilm formation of the ΔBCAM0581 without supplementation, supplemented with supernatant of the ΔcepIΔcciI mutant or ΔBCAM0581 mutant or supplemented with BDSF (5 µM). The relative amount of metabolically active cells was quantified with CellTiter Blue (black bars), while the relative amount of total biomass was quantified with crystal violet (grey bars).
Figure 7Protease production in various B. cenocepacia strains in the abscence (CTRL) and presence of AHL (5 µM), BDSF (5 µM) or both AHL/BDSF (5 µM).
*: significantly different protease production compared to no signal (p<0.05).
Expression of the QS-genes cepI/R and cciI/R and virulence genes zmpA, lipA, lipB and orbI in the ΔBCAM0581, ΔcepIΔcciI and triple mutant in the absence (CTRL) and presence of signal molecules (5 µM).
| Gene name or ID | Fold changes compared to | |||||
| Δ | Δ | Δ | ||||
| CTRL | +BDSF | CTRL | +AHL | CTRL | +BDSF/AHL | |
|
| −3.3 | 1.1 | ND | ND | ND | ND |
|
| −2.0 | −1.6 | −1.1 | −1.2 | 1.7 | −1.9 |
|
| −7.2 | −1.9 | ND | ND | ND | ND |
|
| −2.5 | −1.5 | −1.4 | 1.8 | −2.6 | −1.4 |
|
| −18.1 | −2.2 | −12.6 | −1.6 | −17.9 | −1.2 |
|
| −9.6 | −1.9 | −3.1 | −1.6 | −3.4 | 1.3 |
|
| −2.0 | 2.2 | −8.8 | −4.3 | −4.2 | −1.1 |
|
| −2.2 | 2.6 | −2.1 | 1.0 | −4.3 | 3.0 |
ND: not detected.
significantly different gene expression compared to WT (p<0.05).
significantly different gene expression compared to gene expression in the absence of supplementation with AHL, BDSF or AHL/BDSF (p<0.05).
Strains and plasmids used.
| Strain/plasmid | Properties | Source/reference |
|
| ||
| J2315 | WT |
|
| Δ | J2315 ΔBCAM1870 | This study |
| Δ | J2315 ΔBCAM0239a | This study |
| ΔBCAM0581 | J2315 ΔBCAM0581 | This study |
| Δ | J2315 ΔBCAM1870ΔBCAM0239a | This study |
| Δ | J2315 ΔBCAM1870ΔBCAM0581 | This study |
| Δ | J2315 ΔBCAM0239aΔBCAM0581 | This study |
| Δ | J2315 ΔBCAM0239aΔBCAM1870ΔBCAM0581 | This study |
|
| ||
| DH5a | F−Φ80d | Laboratory stock |
| SY327 |
| M. Valvano |
| OP50 | WT | Laboratory stock |
| JB523 | pJBA130 Tetr pME6031- |
|
|
| ||
| pGEM-T Easy | Vector for PCR cloning, Ampr | Promega |
| pGPI |
| M. Valvano |
| pRK2013 |
| M. Valvano |
| pDAI | pDA12 encoding the I | M. Valvano |
Ampr, ampicillin resistance; Catr, chloramphenicol resistance; Kanr, kanamycin resistance; Rifr, rifampin resistance; Tetr, tetracycline resistance; Tpr, trimethoprim resistance.
Primers used in this work.
| Primer name | Primer sequence | Restriction enzyme |
| KOcepIXL |
|
|
| KOcepIBL |
|
|
| KOcepIBR |
|
|
| KOcepIKR |
|
|
| KOcciIXL | 5′-TT |
|
| KOcciIBL | 5′-TT |
|
| KOcciIBR |
|
|
| KOcciIKR |
|
|
| KO0581XL | 5′-TT |
|
| KO0581BL | 5′-TT |
|
| KO0581BR | 5′-TT |
|
| KO0581KR | 5′-TT |
|
| COcepIFL |
| |
| COcepIRR |
| |
| COcciIFL | 5′-ATTCTTCCGTCAGCCA-3′ | |
| COcciIRR | 5′-TCTCGCCAGTCCGTCG-3′ | |
| CO0581FL |
| |
| CO0581RR | 5′-CCAGCGGGAAGGAGAT-3 | |
| CepI FW (qPCR) |
| |
| CepI RV (qPCR) |
| |
| CepR FW (qPCR) |
| |
| CepR RV (qPCR) |
| |
| CciI FW (qPCR) |
| |
| CciI RV (qPCR) | 5′-CCGCTCCGGGTAACTGCCAA-3 | |
| CciR FW (qPCR) | 5′-GCTGGCCACCGCCTTTCTCA-3 | |
| CciR RV (qPCR) |
| |
| ZmpA FW (qPCR) |
| |
| ZmpA RV (qPCR) |
| |
| LipA FW (qPCR) |
| |
| LipA RV (qPCR) |
| |
| LipB FW (qPCR) |
| |
| LipB RV (qPCR) |
| |
| OrbI FW (qPCR) |
| |
| OrbI RV (qPCR) |
| |
| BCAM2784FW (qPCR) |
| |
| BCAM2784 RV (qPCR) |
| |
| BCAS0175 FW (qPCR) |
| |
| BCAS0175 RV (qPCR) |
| |
| BCAL2694 FW (qPCR) |
| |
| BCAL2694 RV (qPCR) |
|
Restriction endonuclease sites incorporated in the oligonucleotide sequences are underlined.